Close Menu
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
Advertisement
X (Twitter) LinkedIn Facebook
X (Twitter) LinkedIn Facebook YouTube
OncologyTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
Subscribe
OncologyTube
Home » ASCO » ATOMIC Trial Results at ASCO 2025: Breakthrough for dMMR Stage III Colon Cancer
ASCO

ATOMIC Trial Results at ASCO 2025: Breakthrough for dMMR Stage III Colon Cancer

EditorBy EditorJune 1, 2025Updated:June 4, 2025No Comments2 Mins Read
Twitter LinkedIn Facebook Email
Share
Twitter LinkedIn Facebook Email

Ask about FDA oncology approvals, clinical trials, and treatment guidelines.

ATOMIC Trial ASCO 2025: Key Results Revealed
On June 1, 2025, the ASCO Annual Meeting in Chicago presented the ATOMIC trial ASCO 2025 results. This phase III study focuses on stage III dMMR colon cancer treatment. Researchers tested atezolizumab with mFOLFOX6 against mFOLFOX6 alone. The trial showed a clear improvement in disease-free survival for patients. This post explains the findings for oncology professionals.

Details of the ATOMIC Trial
The ATOMIC trial included 712 patients with dMMR stage III colon cancer. From 2017 to 2023, researchers divided them into two groups. One group of 355 patients received atezolizumab and mFOLFOX6. The other group of 357 patients got only mFOLFOX6. The median age was 64 years, and 55.1% were women. Also, 83.8% had proximal tumors. About 46.1% were low risk, while 53.9% were high risk.

Disease-Free Survival Data from ATOMIC Trial ASCO 2025
The results showed a difference in outcomes. Patients on atezolizumab with mFOLFOX6 had a three-year DFS of 86.4%. In contrast, the mFOLFOX6-only group had a DFS of 76.6%. The hazard ratio was 0.50, with a 95% CI of 0.35 to 0.72. Additionally, the p-value was below 0.0001. This exceeded the efficacy boundary of 0.009, confirming the benefit of the combined treatment.

Safety and Subgroup Analysis
Safety data highlighted some differences. The atezolizumab group had grade 3 or higher adverse events in 71.7% of cases. Meanwhile, the mFOLFOX6 group saw these events in 62.1% of patients. Importantly, the treatment was effective across all subgroups. This included both low-risk and high-risk patients, showing consistent results.

Implications for dMMR Colon Cancer Care
The ATOMIC trial ASCO 2025 findings may influence future treatment approaches. Adding atezolizumab to mFOLFOX6 improves DFS for dMMR stage III colon cancer. As a result, this combination could become a preferred option for adjuvant therapy. Oncologists may consider this approach to help patients stay cancer-free longer.

More ASCO 2025 Insights
Learn more about the ATOMIC trial ASCO 2025 results by viewing Erman Akkus’ infographic on X . For additional oncology research, explore our ASCO 2025 research page. Also, visit our colon cancer treatment updates for related information. Stay informed with the latest in cancer care.

Related Links:

????????ATOMIC#ASCO25

➡️Adj atezolizumab + FOLFOX vs FOLFOX in stage III dMMR colon ca

✅3-y DFS: 86.4% vs 76.6%
HR: 0.50, P<0.0001@OncoAlert @ASCO #cancer #oncology #MedX #colon pic.twitter.com/2vW3gyWKAs

— Erman Akkus (@Erman_Akkus) June 1, 2025

https://dailynews.ascopubs.org/do/asco25-first-look-dr-julie-gralow-atomic?cid=DM21105&bid=498898895

ATOMIC way vs Niche 2 way .
12 cycles post op or 2 cycles neo adjuvant
What will u do ?
????ATOMIC Trial | #ASCO25 Plenary
Adjuvant Atezo???? + mFOLFOX6 in stage III dMMR colon cancer
✅ DFS benefit:
???? 3-yr DFS 86.4% vs 76.6%
⚖️ HR 0.50 | p<0.0001
BUT… is 12+13 cycles of therapy… pic.twitter.com/NGUEp3UNBs

— Dr Amol Akhade (@SuyogCancer) June 1, 2025
BRAFTOVI BREAKWATER Trial: Survival Results at ASCO 2025
ASCO ASCO 2025 Atezolizumab ATOMIC Trial Colon Cancer Treatment Disease-Free Survival dMMR colon cancer mFOLFOX6 Oncology Research stage III colon cancer
Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News
Share. Twitter LinkedIn Facebook Email

Related Posts

Prof. Tao Zhu presenting AACR 2026 data on QHS-5132, showing a 55.6% response rate and a waterfall plot of tumor shrinkage for platinum-resistant ovarian cancer.

Does QHS-5132 Signal a Biomarker-Agnostic Shift in Ovarian Cancer Treatment?

AACR 3 Mins Read
Large white text overlaying the left side of the image asks, "BETTER THAN BLOOD THINNERS?" with the Desert Valley Hospital logo positioned below the text.

Are We Under-Treating PE in Cancer Patients?

Conference Coverage 2 Mins Read
Dr. Joshua G. Cohen, MD, City of Hope - 2026 Cancer Breakthroughs at MOASC Summit

2026 Cancer Breakthroughs: Dr. Joshua Cohen’s Top Takeaways from the MOASC Summit

Breast Cancer 4 Mins Read
Connect With Us on Social
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

Latest FDA Oncology Updates

Accepted for Review Oncology Press Release

FDA Accepts NDA for TLX101-Px (Pixclara®) - PR Newswire

FDA Accepts NDA for TLX101-Px (Pixclara®). (PRNewsfoto/Telix Pharmaceuticals ... cancer), and has assigned a PDUFA goal date of September 11, 2026 ...

Filed: Sep 11, 2026 View source on FDA.gov →
ODAC Meeting Oncology FDA ODAC

April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee

Event Title. April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. April 30, 2026 · On This Page · Agenda · Meeting Materials.

Meeting: Apr 30, 2026 View source on FDA.gov →
PDUFA Date Oncology Press Release

Savara Announces the U.S. Food & Drug Administration (FDA) Has ...

Such statements include, but are not limited to, statements related to the target PDUFA action date. Savara may not actually achieve any of the matters ...

View source on FDA.gov →
Approval Heme FDA OCE

FDA approves nivolumab with chemotherapy for Hodgkin lymphoma

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent ...

View source on FDA.gov →
News Oncology FDA OCE

FDA Oncology Center of Excellence Presents Conversations on ...

FDA Oncology Center of Excellence Presents Conversations on Cancer: Oncology Nurses - Frontliners in Oncology May 6, 2026.

View source on FDA.gov →
News Oncology FDA OCE

FDA Schedules Public Meeting on the Commissioner's National ...

... Oncology Center of Excellence, as well as a presiding officer. Requests to speak are due by April 24 at 11:59 p.m. The FDA is also soliciting written ...

View source on FDA.gov →
Approval GYN FDA.gov

FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

Approved: Mar 25, 2026 View source on FDA.gov →
Approval Heme FDA.gov

FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

Approved: Mar 20, 2026 View source on FDA.gov →
Recent Posts
  • Does QHS-5132 Signal a Biomarker-Agnostic Shift in Ovarian Cancer Treatment?
  • Is Alisertib the New Standard for Overcoming Resistance in KRAS G12C-Mutant NSCLC?
  • Can Zoldonrasib Redefine Treatment for KRAS G12D NSCLC?
  • Are We Under-Treating PE in Cancer Patients?
  • Is MammaPrint High Risk the New Standard for Guiding Immunotherapy?
X (Twitter) LinkedIn Facebook YouTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
© 2026 Copyright Protected Medicus Networks, Inc. Privacy Policy

Type above and press Enter to search. Press Esc to cancel.